AU770307B2 - PGE synthase and methods and means for modulating its activity - Google Patents

PGE synthase and methods and means for modulating its activity Download PDF

Info

Publication number
AU770307B2
AU770307B2 AU15041/00A AU1504100A AU770307B2 AU 770307 B2 AU770307 B2 AU 770307B2 AU 15041/00 A AU15041/00 A AU 15041/00A AU 1504100 A AU1504100 A AU 1504100A AU 770307 B2 AU770307 B2 AU 770307B2
Authority
AU
Australia
Prior art keywords
polypeptide
pge
pge synthase
seq
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU15041/00A
Other languages
English (en)
Other versions
AU1504100A (en
Inventor
Per-Johan Jakobsson
Ralf Morgenstern
Bengt Samuelsson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Karolinska Innovations AB
Original Assignee
Karolinska Innovations AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Karolinska Innovations AB filed Critical Karolinska Innovations AB
Publication of AU1504100A publication Critical patent/AU1504100A/en
Priority to AU2003271297A priority Critical patent/AU2003271297B2/en
Application granted granted Critical
Publication of AU770307B2 publication Critical patent/AU770307B2/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/551—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being inorganic
    • G01N33/553—Metal or metal coated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Inorganic Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
AU15041/00A 1998-11-09 1999-11-02 PGE synthase and methods and means for modulating its activity Expired AU770307B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003271297A AU2003271297B2 (en) 1998-11-09 2003-12-19 PGE synthase and methods and means for modulating its activity

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10768798P 1998-11-09 1998-11-09
US60/107687 1998-11-09
PCT/EP1999/008363 WO2000028022A1 (en) 1998-11-09 1999-11-02 Pge synthase and methods and means for modulating its activity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2003271297A Division AU2003271297B2 (en) 1998-11-09 2003-12-19 PGE synthase and methods and means for modulating its activity

Publications (2)

Publication Number Publication Date
AU1504100A AU1504100A (en) 2000-05-29
AU770307B2 true AU770307B2 (en) 2004-02-19

Family

ID=22317930

Family Applications (1)

Application Number Title Priority Date Filing Date
AU15041/00A Expired AU770307B2 (en) 1998-11-09 1999-11-02 PGE synthase and methods and means for modulating its activity

Country Status (9)

Country Link
US (4) US6395502B1 (enExample)
EP (1) EP1129188B1 (enExample)
JP (2) JP4503849B2 (enExample)
AT (1) ATE305040T1 (enExample)
AU (1) AU770307B2 (enExample)
CA (1) CA2349529C (enExample)
DE (1) DE69927400T2 (enExample)
ES (1) ES2249042T3 (enExample)
WO (1) WO2000028022A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69927400T2 (de) * 1998-11-09 2006-06-29 Karolinska Innovations Ab Pge synthase und verfahren und mitteln zur modulation deren aktivität
WO2001057225A1 (fr) * 2000-02-03 2001-08-09 Chugai Seiyaku Kabushiki Kaisha Proteine regissant l'activite de la pge2 synthase et son utilisation
AU2002323358A1 (en) * 2001-08-24 2003-03-10 Karoliska Innovations Ab Methods for preparing purified prostaglandin e synthase
IL161831A0 (en) * 2001-11-30 2005-11-20 Pfizer Prod Inc Disruption of the prostaglandin e synthase 2 gene
EP1575498A2 (en) * 2002-09-25 2005-09-21 Pharmacia Corporation Antisense modulation of microsomal prostaglandin e2 synthase expression
WO2004067766A1 (en) * 2003-01-27 2004-08-12 Pfizer Products Inc. Novel methods involving the determination of activity of enzymes that use or produce prostaglandin endoperoxide h2
WO2005024059A2 (en) * 2003-09-09 2005-03-17 Karolinska Innovations Ab Methods for identifying compounds for inhibiting fever
US7638331B2 (en) 2004-01-02 2009-12-29 The Administration of the Tulane Rducation Fund Directed apoptosis in COX-2 overexpressing cancer cells through expression targeted gene delivery
CA2639412A1 (en) * 2007-09-11 2009-03-11 Universite Laval Prostaglandin e2 modulation and uses thereof
CN117323320B (zh) * 2023-11-20 2025-10-31 复旦大学附属中山医院 长链脂肪酸12-hht在睡眠呼吸暂停合并高血压中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US914356A (en) * 1901-11-30 1909-03-02 Harry Ward Leonard Electric-circuit controller.
EP1015624A2 (en) * 1997-09-17 2000-07-05 The Johns Hopkins University P53-induced apoptosis
DE69927400T2 (de) * 1998-11-09 2006-06-29 Karolinska Innovations Ab Pge synthase und verfahren und mitteln zur modulation deren aktivität

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
EMBL AU NO. AF 027740 *

Also Published As

Publication number Publication date
CA2349529C (en) 2009-10-27
US7192733B2 (en) 2007-03-20
DE69927400D1 (de) 2006-02-02
US7067296B2 (en) 2006-06-27
US20030064493A1 (en) 2003-04-03
ATE305040T1 (de) 2005-10-15
AU1504100A (en) 2000-05-29
JP2002539762A (ja) 2002-11-26
US6395502B1 (en) 2002-05-28
JP4503849B2 (ja) 2010-07-14
WO2000028022A1 (en) 2000-05-18
US7645601B2 (en) 2010-01-12
CA2349529A1 (en) 2000-05-18
EP1129188A1 (en) 2001-09-05
JP2010115205A (ja) 2010-05-27
ES2249042T3 (es) 2006-03-16
EP1129188B1 (en) 2005-09-21
DE69927400T2 (de) 2006-06-29
US20050118696A1 (en) 2005-06-02
US20080153107A1 (en) 2008-06-26

Similar Documents

Publication Publication Date Title
US7645601B2 (en) Methods and means for modulating PGE synthase activity
THOMSON et al. Sequence, catalytic properties and expression of chicken glutathione-dependent prostaglandin D2 synthase, a novel class Sigma glutathione S-transferase
Soupene et al. Activity of the acyl-CoA synthetase ACSL6 isoforms: role of the fatty acid Gate-domains
JP2005534279A (ja) 新規なシクロオキシゲナーゼ変異体とその使用方法
Ruan et al. Amino-terminal topology of thromboxane synthase in the endoplasmic reticulum.
Wu et al. Characterization of PPIB interaction in the P3H1 ternary complex and implications for its pathological mutations
AU2003271297B2 (en) PGE synthase and methods and means for modulating its activity
Bechor et al. p67 phox binds to a newly identified site in Nox2 following the disengagement of an intramolecular bond—Canaan sighted?
JP2003528638A (ja) 単離ヒト薬剤代謝タンパク、ヒト薬剤代謝タンパクをコード化する核酸分子、及びその使用
JP2005526483A (ja) 精製されたプロスタグランジンｅシンターゼを調製するための方法
Monfregola et al. Functional analysis of TMLH variants and definition of domains required for catalytic activity and mitochondrial targeting
Pettersson et al. Human microsomal prostaglandin E synthase 1: a member of the MAPEG protein superfamily
WO2005019472A1 (ja) シノビオリン活性調節作用の検出方法
Svartz et al. Leukotriene C4 synthase homo-oligomers detected in living cells by bioluminescence resonance energy transfer
JP2007520208A (ja) コア２β−１，６−Ｎ−アセチルグリコサミニルトランスフェラーゼの変異体
JPH10117788A (ja) ヒト・ｍｙｔ−１キナーゼクローン
US20090312245A1 (en) SRA binding protein
US6262234B1 (en) Nuclear receptor polypeptide ZPPAR4
JP2002300880A (ja) 新規ユビキチン特異プロテアーゼ
JP2002519034A (ja) ヒト酸化還元酵素タンパク質
WO2004058957A2 (en) Canine cyp1a2 sequences
US20040161803A1 (en) Methods and reagents for identifying weight loss promoters and therpeutic uses therefor
WO2002079501A1 (en) Methods and reagents for identifying weight loss promoters and therapeutic uses therefor
JP2001302692A (ja) ＩκＢαのユビキチン化を阻害しうる試験化合物をスクリーニングする為の競合試験およびキット
JP2004524809A (ja) 単離ヒトホスホリパーゼタンパク質、ヒトホスホリパーゼタンパク質をコード化する核酸分子及びその使用

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired